Acumen Pharmaceuticals/ABOS

$3.16

-8.93%
-
1D1W1MYTD1YMAX

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The Company is developing ACU193 for intravenous (IV), administration every four weeks for the treatment of early AD, which is in Phase I clinical trial.

Ticker

ABOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel O'Connell

Employees

51

Headquarters

Charlottesville, United States

ABOS Metrics

BasicAdvanced
$212.08M
Market cap
-
P/E ratio
-$1.08
EPS
-
Beta
-
Dividend rate
$212.08M
$11.31
$1.81
356.06K
19.013
11.199
11.482
-20.67%
-22.98%
-21.56%
0.766
0.794
-2.55%

What the Analysts think about ABOS

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
305.06% upside
High $15.00
Low $10.00
$3.16
Current price
$12.80
Average price target

ABOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-16.4M
27.13%
Profit margin
0%
-

ABOS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.69%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.28
-$0.28
-$0.24
-$0.28
-
Expected
-$0.35
-$0.35
-$0.27
-$0.26
-$0.26
Surprise
-19.08%
-19.08%
-9.77%
7.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Acumen Pharmaceuticals stock?

Acumen Pharmaceuticals (ABOS) has a market cap of $212.08M as of April 19, 2024.

What is the P/E ratio for Acumen Pharmaceuticals stock?

The price to earnings (P/E) ratio for Acumen Pharmaceuticals (ABOS) stock is 0 as of April 19, 2024.

Does Acumen Pharmaceuticals stock pay dividends?

No, Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Acumen Pharmaceuticals dividend payment date?

Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Acumen Pharmaceuticals?

Acumen Pharmaceuticals (ABOS) does not currently have a Beta indicator.

What is the Acumen Pharmaceuticals stock price target?

The target price for Acumen Pharmaceuticals (ABOS) stock is $12.8, which is 305.06% above the current price of $3.16. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Acumen Pharmaceuticals stock

Buy or sell Acumen Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing